A Phase 2 interventional study of rituximab [MabThera/Rituxan] and Methotrexate in Lymphoma, sponsored by Hoffmann-La Roche. Terminated at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-08.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 253 studies testing rituximab in Lymphoma — 11 open to participants now, 17 under way, 2 of them phase 3. Rituximab · Lymphoma.
Among the 253 studies testing rituximab in Lymphoma, this one is the 216th largest by enrollment of the 237 interventional ones that give a count, is one of 14 that started in 2007, is one of 158 in phase 2, and was the 136th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →11 of the 253 studies testing rituximab in Lymphoma are open now, in 7 countries. Recruiting first, the newest first:
Gottfried von Keudell, MD PhD · Sites in United States
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Portugal, Spain
Ages 18+
Second Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Christine Ryan · Sites in United States
Ages 18+
Christian Buske · Sites in Germany, Greece
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
253 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 184 · Phase 3 28
First in 1995; this study’s year is marked. 14 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 44 across the 237 interventional studies. Of the 212 that completed or were terminated, 102 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 253 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
17 studies in Lymphoma by Hoffmann-La Roche: 1 open now, 3 under way, 1 of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 17 studies in Lymphoma by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2007, is one of 3 in phase 2, and was the 3rd registered.
Hoffmann-La Roche’s Lymphoma studies by the year they started, since 2002.
3 of the studies testing rituximab in Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06573645Phase 3Xia YiA Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | 2027-01-12 |
| NCT05495464M.D. Anderson Cancer CenterA Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | 2027-03-31 |
| NCT06557330Fox Chase Cancer CenterMRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | 2027-09-29 |
Add all 3 to your calendar (.ics) → With an account.
Among the 253 studies testing rituximab in Lymphoma, from their registry updates:
Among Hoffmann-La Roche’s 17 in Lymphoma:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of MabThera plus high dose methotrexate plus high dose cytarabine in patients with central nervous system non-Hodgkin's lymphoma. Eligible patients will receive a treatment regimen consisting of MabThera (750mg/m2 iv) plus methotrexate (8g/m2 iv) given at intervals up to week 22, plus cytarabine (2g/m2 iv) at week 11 and week 22. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan] · Drug: Methotrexate · Drug: Cytarabine
Drug page: Rituximab
750mg/m2 iv
8g/m2 iv
2g/m2 iv
Percentage of Participants With a Complete Response (CR) or Unconfirmed CR (CRu)
CR: complete disappearance of all enhancing abnormalities on contrast-enhanced cranial magnetic resonance imaging (MRI); no evidence of active ocular lymphoma as defined by absence of cells in the vitreous and resolution of any previously documented retinal or optic nerve infiltrates; negative cerebrospinal fluid (CSF) cytology; at the time of CR determination, participant had discontinued use of all corticosteroids for at least 2 weeks. CRu requires fulfillment of CR criteria but with these limitations: Fulfills CR criteria but had continued requirement for corticosteroid therapy at any dose; small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; persistent minor abnormality on follow-up ophthalmologic exam (related to persistent non-malignant cells in vitreous, or alterations in retina/optic nerve not consistent with tumor infiltration) if the abnormality is unlikely to represent ocular lymphoma.
Time frame: Week 24
Percentage of Participants With a CR, CRu or Partial Response (PR)
PR: greater than or equal to (≥) 50 percent (%) decrease in the contrast-enhancing lesion seen on MRI as compared with the baseline images; (2) Corticosteroid dose was irrelevant to the determination of PR; for participants with ocular disease, ophthalmologic exam must show a decrease in vitreous cell count or retina/optic nerve cellular infiltrate but may have continued to show persistent malignant or suspicious cells; for participants with CSF positive for neoplastic cells, CSF cytology may be negative or continue to show persistent malignant or suspicious cells in patients with ≥50% decrease in the primary brain lesions; no new sites of disease.
Time frame: Week 24
Percentage of Participants With Initial CR or CRu and Subsequent Disease Relapse
Time frame: Week 24
Overall Survival
Time from entry into trial until death of any cause. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last dose and participants with no post baseline information were censored at the baseline date.
Time frame: Time of last follow-up assessment between Day 1 and 3 years
Progression-Free Survival (PFS)
PFS was defined as the time interval between the entry into trial and occurrence of one of the following events: progression of disease (PD) or death as a result of primary central nervous system lymphoma (PCNSL). Participants who were withdrawn from the study without documented progression and for whom there existed case report form (CRF) evidence that evaluations had been made, were censored at the date of last tumor assessment when participant was known to be progression free. Participants without postbaseline tumor assessments but known to be alive were censored at the time of randomization. PD required a ≥25% increase in the contrast-enhanced lesion seen on MRI as compared with baseline or best response (comparison should be made to the smallest of multiple lesions); progression of ocular disease as indicated by an increase in vitreous cell count or progressive retinal or optic nerve infiltration, appearance of any new lesion or site of disease during or at the end of therapy.
Time frame: Week 24
| Milestone | Rituximab, Cytarabine, and Methotrexate (MTX) |
|---|---|
| Started | 5 |
| Completed | 0 |
| Not completed | 5 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Administrative error | 1 |
| Withdrew: Study terminated by sponsor | 2 |
CR: complete disappearance of all enhancing abnormalities on contrast-enhanced cranial magnetic resonance imaging (MRI); no evidence of active ocular lymphoma as defined by absence of cells in the vitreous and resolution of any previously documented retinal or optic nerve infiltrates; negative cerebrospinal fluid (CSF) cytology; at the time of CR determination, participant had discontinued use of all corticosteroids for at least 2 weeks. CRu requires fulfillment of CR criteria but with these limitations: Fulfills CR criteria but had continued requirement for corticosteroid therapy at any dose; small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; persistent minor abnormality on follow-up ophthalmologic exam (related to persistent non-malignant cells in vitreous, or alterations in retina/optic nerve not consistent with tumor infiltration) if the abnormality is unlikely to represent ocular lymphoma.
No measurements were reported for this outcome.
PR: greater than or equal to (≥) 50 percent (%) decrease in the contrast-enhancing lesion seen on MRI as compared with the baseline images; (2) Corticosteroid dose was irrelevant to the determination of PR; for participants with ocular disease, ophthalmologic exam must show a decrease in vitreous cell count or retina/optic nerve cellular infiltrate but may have continued to show persistent malignant or suspicious cells; for participants with CSF positive for neoplastic cells, CSF cytology may be negative or continue to show persistent malignant or suspicious cells in patients with ≥50% decrease in the primary brain lesions; no new sites of disease.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Time from entry into trial until death of any cause. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last dose and participants with no post baseline information were censored at the baseline date.
No measurements were reported for this outcome.
PFS was defined as the time interval between the entry into trial and occurrence of one of the following events: progression of disease (PD) or death as a result of primary central nervous system lymphoma (PCNSL). Participants who were withdrawn from the study without documented progression and for whom there existed case report form (CRF) evidence that evaluations had been made, were censored at the date of last tumor assessment when participant was known to be progression free. Participants without postbaseline tumor assessments but known to be alive were censored at the time of randomization. PD required a ≥25% increase in the contrast-enhanced lesion seen on MRI as compared with baseline or best response (comparison should be made to the smallest of multiple lesions); progression of ocular disease as indicated by an increase in vitreous cell count or progressive retinal or optic nerve infiltration, appearance of any new lesion or site of disease during or at the end of therapy.
No measurements were reported for this outcome.
Collected over Baseline up to 24 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab, Cytarabine, and MTX | — | 0/5 (0%) | 5/5 (100%) |
| Event | Rituximab, Cytarabine, and MTX |
|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 5/5 |
| NeutropeniaBlood and lymphatic system disorders | 4/5 |
| ConstipationGastrointestinal disorders | 3/5 |
| NauseaGastrointestinal disorders | 3/5 |
| FatigueGeneral disorders | 3/5 |
| HyperthermiaGeneral disorders | 3/5 |
| Oedema peripheralGeneral disorders | 3/5 |
| Drug toxicityInjury, poisoning and procedural complications | 3/5 |
| HeadacheNervous system disorders | 3/5 |
| Abdominal painGastrointestinal disorders | 2/5 |
Safety population: all participants who received any amount of study drug.
| Age, Continuous(years) | Rituximab, Cytarabine, and MTX |
|---|---|
| Mean | 59.8 ± 8.23 |
| Sex: Female, Male(Participants) | Rituximab, Cytarabine, and MTX |
|---|---|
| Female | 2 |
| Male | 3 |
The record gives a start of Sep 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rituximab · Methotrexate · Cytarabine